Iranian Journal of Neurology 2017. 16(2):.

Hemangioblastoma on the cerebellum of a patient undergoing long-term use of natalizumab for multiple sclerosis
Yara Dadalti Fragoso, Joseph Bruno Bidin Brooks, Mateus Reghin Neto

Abstract


-

Keywords


Multiple Sclerosis; Natalizumab; Brain Neoplasms

References


- Stüve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci. 2008;274:39-41.

doi: 10.1016/j.jns.2008.03.022.

- Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59:743-7.

- Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol. 2009;66:403-6.

doi: 10.1002/ana.21782.

- Na A, Hall N, Kavar B, King J. Central nervous system lymphoma associated with natalizumab. J Clin Neurosci. 2014;21:1068-70.

doi: 10.1016/j.jocn.2013.10.018.

- Matzke M, Schreiber S, Elolf E, et al. Natalizumab-associated central nervous system lymphoma? - another patient. Mult Scler. 2012;18:1653-4.

doi: 10.1177/1352458512439336.

- Bozic C, LaGuette J, Panzara MA, Sandrock AW. Natalizumab and central nervous system lymphoma: no clear association. Ann Neurol. 2009;66:261-2.

doi: 10.1002/ana.21835.

- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (Cleveland) 1983;33:1444-52.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.